Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Overall Survival 1Melanoma 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Heart Diseases 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Cardiotoxicity 1

Interventions

pembrolizumab 20Carboplatin 14Cyclophosphamide 12atezolizumab 11Paclitaxel 10Albumin-Bound Paclitaxel 8Capecitabine 7Nivolumab 6130-nm albumin-bound paclitaxel 6spartalizumab 5fludarabine 5Taxes 5Gemcitabine 5talazoparib 4bintrafusp alfa protein, human 4avelumab 4Cisplatin 4sacituzumab govitecan 3olaparib 3entinostat 3Leucovorin 3Ipilimumab 3Immunoglobulin G 3Drug Therapy 3Doxorubicin 3Docetaxel 3Biopsy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3trilaciclib 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Triple Negative Breast Neoplasms × Atorvastatin × Clear all
NCT03872388 2024-10-02

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 8 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡